WilmerHale Advises Dyne Therapeutics on its $402.5 Million Public Offering of Common Stock

WilmerHale Advises Dyne Therapeutics on its $402.5 Million Public Offering of Common Stock

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale advised Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, on its underwritten public offering of 21,827,549 shares of common stock at a public offering price of $18.44 per share. This includes 2,847,071 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds to Dyne from the offering were approximately $402.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All shares in the offering were sold by Dyne.

The WilmerHale team was led by Stuart Falber and Scott Lunin, and included Erin Bruynell Gallagher, Sam Wizon, and Abigail King.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel